Towards Healthcare
North America Life Science Market to Surge USD 102.47 Bn by 2034

North America Life Science Market Expands with AI and Genomics

Market insights predict the global North America life science industry will increase from USD 35.39 billion in 2024 to USD 102.47 billion by 2034, achieving a CAGR of 11.22%. The North America life science market is expanding due to a growing R&D ecosystem. The U.S. led the market due to the growth in R&D investments.

  • Insight Code: 6278
  • No. of Pages: 150+
  • Format: PDF/PPT/Excel
  • Published: October 2025
  • Report Covered: [Revenue + Volume]
  • Historical Year: 2021-2022
  • Base Year: 2023
  • Estimated Years: 2024-2033

About The Author

Rohan Patil is a seasoned market research professional with over 5 years of focused experience in the healthcare sector, bringing deep domain expertise, strategic foresight, and analytical precision to every project he undertakes.

He began his journey with Precedence Research, where he played a pivotal role in developing high-impact healthcare market reports. Today, Rohan leads research initiatives at Towards Healthcare, while also contributing to Statifacts, where he supports cross-industry analysis and data-driven storytelling.

Rohan’s core strengths lie in trend analysis and emerging technologies, regulatory monitoring and thought leadership through high-quality report writing. He excels at identifying future-ready opportunities and translating complex data into strategic recommendations. His work spans pharmaceuticals, biotechnology, medical devices, and digital health, assessing everything from market potential and competitive positioning to customer needs and regulatory shifts.

A trusted advisor and a relentless innovator, Rohan continues to push the boundaries of traditional market research, merging scientific rigor with commercial insight to stay ahead in a fast-evolving healthcare landscape.

FAQ's

The North America life science market holds a valuation of USD 39.31 billion as of 2025, and will expand to USD 102.47 billion by 2034, achieving a CAGR of 11.22% between 2024 and 2034.

The U.S. is currently leading the North America life science market share 88% due to the growth in R&D investments.

Some key players include Gilead Sciences, Moderna, Inc., Biogen Inc., and Regeneron Pharmaceuticals.

The use of AI in North America life sciences is increasing as it helps in accelerating drug discovery and development, enhances the development of personalized medicine, diagnostics, and provides AI virtual cell models.

Ministry of Health and Family Welfare, Government of India, National Institutes of Health, FDA, WHO, PIB, CDC.